September 23, 2017August 24, 2022
EU Approves Roche’s Tecentriq to Treat Non-small Cell Lung Cancer
News
The European Commission (EC) granted marketing authorization to Roche for Tecentriq (atezolizumab) as a monotherapy for patients with locally advanced or metastatic non-small cell lung ... Read more
July 18, 2017July 18, 2017
Elderly Patients With Early-stage Lung Cancer Good Candidates For SBRT, Study Suggests
News
Elderly people with early-stage lung cancer might also benefit from stereotactic body radiation therapy (SBRT), finds a study of more than ... Read more
July 13, 2017
Pharmatest Develops ‘Humanized’ Mouse Model of Bone Metastasis to Study New Therapies
News
Pharmatest Services, in collaboration with Taconic Biosciences, has developed a new experimental mouse model with a human immune system specifically ... Read more
July 11, 2017
FDA Grants Orphan Drug Status to TPX-0005 for Non-small Cell Lung Cancers with Gene Mutations
News
U.S. regulators have granted orphan drug status to TP Therapeutics’ TPX-0005 as a treatment for non-small cell lung cancers with ... Read more
July 6, 2017
Mutation Burden and PD-L1 Levels Can Help Predict Patient’s Response to Opdivo, Study Finds
News
Genetic characterization and the detection of PD-1 ligand protein (PD-L1) levels in non-small cell lung cancers (NSCLC) can help oncologists ... Read more
June 29, 2017
Patient Enrollment Paused in Phase 3 Trial of Tedopi in NSCLC
News
OSE Immunotherapeutics has temporarily paused patient enrollment in a Phase 3 clinical trial evaluating Tedopi (OSE2101) for non-small cell lung ... Read more
June 27, 2017June 27, 2017
Memory T-cells Within Lung Tumors Predict Good Patient Outcome, Study Shows
News
Researchers have identified a subset of immune T-cells that improve the effectiveness of immunotherapies in lung cancer, and may help ... Read more
June 26, 2017June 26, 2017
FDA Approves Tafinlar, Mekinist Combo to Treat BRAF V600E Non-Small Cell Lung Cancer
News
The U.S. Food and Drug Administration (FDA) announced approval of Tafinlar (dabrafenib) and Mekinist (trametinib) to be delivered in combination for ... Read more
June 22, 2017
Entinostat-Keytruda Clinical Trial in NSCLC Will Proceed to Next Stage
News
A clinical trial exploring entinostat in combination with Merck’s Keytruda (pembrolizumab) in non-small cell lung cancer (NSCLC) patients who progressed ... Read more
June 20, 2017June 20, 2017
ASTRO Issues Guidelines for Using High-dose Focused Radiation in Early-stage Lung Cancer
News
The American Society for Radiation Oncology (ASTRO) has released new guidelines for treating inoperable lung cancer patients with stereotactic body ... Read more
June 15, 2017
70% of Patients with Brain Cancer Originating in the Lungs Responded to Tagrisso, Trial Shows
News
Seventy percent of patients with brain cancer that originated in the lungs responded to treatment with Tagrisso (osimertinib), according to a ... Read more
June 13, 2017
Keytruda Increases Survival of Lung Cancer Patients, Compared with Standard Chemo, Update Shows
lung cancer, News
Keytruda (pembrolizumab) reduced the risk of non-small cell lung cancer patients dying by 37 percent, compared with standard chemotherapy, according to ... Read more

May 11, 2017May 11, 2017

Clinical Trial to Test Biocept’s Target Selector Platform as Diagnosis, Monitoring Tool for Lung Cancer

News

Biocept and the Addario Lung Cancer Medical Institute (ALCMI) will collaborate on a clinical study assessing the efficacy of Biocept’s Target Selector platform to detect circulating biomarkers in patients with lung ... Read more

May 9, 2017

Tagrisso Helps Lung Cancer Patients Whose Disease Resisted Other Therapies, Trial Shows

News

Tagrisso (osimertinib) was more effective than chemotherapy in treating lung cancer patients whose disease had progressed on another treatment, according to a Phase 3 clinical trial. Patients who took Tagrisso ... Read more

May 5, 2017May 5, 2017

Takeda’s Alunbrig Receives FDA Accelerated Approval for Treatment of ALK+ Lung Cancer

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Takeda‘s Alunbrig (brigatinib) to treat ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who either progressed or could not ... Read more

May 4, 2017May 4, 2017

AbbVie’s Veliparib Combo Trial Fails to Improve Lung Cancer Patients’ Survival

News

AbbVie’s oral PARP inhibitor veliparib was ineffective against squamous non-small cell lung cancer (NSCLC) when administered with chemotherapy, a Phase 3 trail indicated. Despite the results, the company said it ... Read more

April 26, 2017April 26, 2017

Tagrisso Receives Full FDA Approval for Treatment of T790M-positive NSCLC

News

AstraZeneca has announced that Tagrisso (osimertinib), a medication that’s been in development for the treatment of non-small cell lung cancer (NSCLC), recently received full approval from the U.S. Food and ... Read more

April 20, 2017

DelMar’s New Chemotherapeutic VAL-083 Shows Promise in TKI-resistant NSCLC

News

DelMar‘s small molecule chemotherapeutic VAL-083 may be a valuable treatment approach for non-small cell lung cancer (NSCLC) patients who are resistant to tyrosine kinase therapy, according to preclinical data presented ... Read more

April 18, 2017April 18, 2017

Opdivo More Than Tripled 5-Year Survival Rates in NSCLC Patients in Phase 1 Study

News

Recent data from a Phase 1 study revealed that Opdivo-treated advanced non-small cell lung cancer (NSCLC) patients have durable responses and a five-year survival rate of 16%, which more than ... Read more

April 13, 2017April 24, 2017

OncoMed Ends Enrollment in Demcizumab Trials, Including Lung Cancer Studies

News

Adding the anti-Dll4 antibody demcizumab to standard-of-care — Abraxane (protein-bound paclitaxel) plus gemcitabine — does not improve progression-free or overall survival in newly diagnosed metastatic pancreatic cancer patients, compared to ... Read more

April 11, 2017April 11, 2017

Genentech’s Alecensa Superior to Xalkori in Newly Diagnosed ALK+ Advanced NSCLC Patients

News

Patients with ALK-positive advanced non-small cell lung cancer (NSCLC) who receive Genentech’s Alecensa (alectinib) as first-line therapy have significantly higher progression-free survival rates compared to those treated with the standard ... Read more

April 6, 2017

Alecensa Improves Progression-Free Survival in Certain Lung Cancer Patients

News

It took a significantly longer time for non-small lung cancer patients who received Roche’s Alecensa (alectinib) to have their disease progress than those who received chemotherapy, according to a Phase 3 clinical ... Read more

EU Approves Roche’s Tecentriq to Treat Non-small Cell Lung Cancer

Elderly Patients With Early-stage Lung Cancer Good Candidates For SBRT, Study Suggests

Pharmatest Develops ‘Humanized’ Mouse Model of Bone Metastasis to Study New Therapies

FDA Grants Orphan Drug Status to TPX-0005 for Non-small Cell Lung Cancers with Gene Mutations

Mutation Burden and PD-L1 Levels Can Help Predict Patient’s Response to Opdivo, Study Finds

Patient Enrollment Paused in Phase 3 Trial of Tedopi in NSCLC

Memory T-cells Within Lung Tumors Predict Good Patient Outcome, Study Shows

FDA Approves Tafinlar, Mekinist Combo to Treat BRAF V600E Non-Small Cell Lung Cancer

Entinostat-Keytruda Clinical Trial in NSCLC Will Proceed to Next Stage

ASTRO Issues Guidelines for Using High-dose Focused Radiation in Early-stage Lung Cancer

70% of Patients with Brain Cancer Originating in the Lungs Responded to Tagrisso, Trial Shows

Keytruda Increases Survival of Lung Cancer Patients, Compared with Standard Chemo, Update Shows